GDS Wealth Management Increases Stock Position in Edwards Lifesciences Corporation $EW

GDS Wealth Management increased its position in Edwards Lifesciences Corporation (NYSE:EW) by 3.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 232,876 shares of the medical research company’s stock after buying an additional 6,878 shares during the quarter. Edwards Lifesciences comprises 1.2% of GDS Wealth Management’s holdings, making the stock its 28th largest position. GDS Wealth Management’s holdings in Edwards Lifesciences were worth $19,853,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter valued at $25,000. True Wealth Design LLC boosted its stake in Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at $28,000. Hantz Financial Services Inc. boosted its stake in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 164 shares during the last quarter. Finally, Dorato Capital Management bought a new position in Edwards Lifesciences during the 4th quarter valued at $29,000. 79.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

EW has been the topic of a number of research analyst reports. UBS Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. Barclays reiterated an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Finally, Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $95.65.

Edwards Lifesciences Stock Performance

EW opened at $84.08 on Friday. The business’s 50 day moving average is $82.08 and its 200-day moving average is $82.41. The stock has a market cap of $48.47 billion, a PE ratio of 44.72, a price-to-earnings-growth ratio of 2.10 and a beta of 0.95. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 22,680 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the sale, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,704,682.56. The trade was a 51.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,747,975.32. The trade was a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 86,058 shares of company stock valued at $7,118,636. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.